A next-generation, anti-CD19 enhanced (or "armored") CAR T-cell product ... and all but one had been treated with a CAR T-cell therapy approved for their lymphoma type. As for safety, the ...

LEXINGTON, Mass. and SINGAPORE, May 12, 2025 /PRNewswire/ -- Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific armored CAR-T therapies for solid tumors ...